Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UPPTHERA manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This single action is under the review of 1 distinct examiner, MAHLUM, JONATHAN DAVIS. The records identify MAHLUM, JONATHAN DAVIS as the busiest examiner.
The prosecution is currently limited to a single distinct art unit. This indicates that the pending matter for UPPTHERA is focused within a specific sub-sector of Biotechnology & Pharmaceuticals. MAHLUM, JONATHAN DAVIS is responsible for the busiest examiner pending action, controlling the immediate path to allowance or further rejection.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569677 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | MAHLUM, JONATHAN DAVIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569677 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | MAHLUM, JONATHAN DAVIS | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569677 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | MAHLUM, JONATHAN DAVIS | 1625 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUPPTHERA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jonathan Davis Mahlum has the most, with 1 of UPPTHERA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
